Abivax pares gain after denying AstraZeneca speculation

Abivax pares gain after denying AstraZeneca speculation
Momentum traders are flagging several health care stocks that may be overheated heading into the new quarter. As of Feb. 18, 2026, elevated RSI readings suggest recent gains could be vulnerable to pullbacks despite strong headlines. AstraZeneca has surged roughly 14% over the https://t.co/eVMOTmA1TE
AstraZeneca profit climbs on cancer and heart drug demand
Walmart joins Nasdaq 100 on January 20, replacing AstraZeneca
AstraZeneca hails major breakthroughs with breast-cancer drugs
AstraZeneca to become latest drugmaker to strike deal with Trump. Its stock is down but outperforming the market.
290.6BUSD
taip
Common Stock
Pertukaran
PINK
Kod matawang
USD
Nama Mata Wang
US Dollar
Nama negara
USA
ISO negara
US
ADALAH DALAM
GB0009895292
CUSIP
-
Sektor
Healthcare
industri
Drug Manufacturers - General
Akhir Tahun Fiskal
December
tarikh IPO
-
Dikemaskini Pada
-
Nisbah PE
31.09
Nisbah PEG
1.67
Nilai buku
29.59
Bahagian Dividen
3.13
Hasil Dividen
1.70%
Bahagian Pendapatan
6.03
Harga Sasaran Wall Street
104.00
Anggaran EPS Tahun Semasa
4.56
Anggaran EPS Tahun Depan
5.06
EPS Anggaran Suku Tahun Semasa
0
Anggaran EPS Suku Tahun Seterusnya
0
Suku Terkini
-
Hasil TTM
58,126,999,552
Keuntungan Kasar TTM
48,395,001,856
EBITDA
20,416,000,000
Margin keuntungan
16.17%
Pulangan Atas Aset TTM
9.06%
Pulangan Atas Ekuiti TTM
21.67%
Hasil Sesaham TTM
37.501
Pertumbuhan Hasil Qtly YOY
12.00%
Eps TTM yang dicairkan
6.03
Pertumbuhan Pendapatan Qtly YOY
78.00%
PE mengekori
31.09
PE ke hadapan
19
Harga Jualan TTM
4.9994
Buku Harga MRQ
6.1782
Hasil Nilai Perusahaan
5
EBITDA Nilai Perusahaan
17
400.00
3.27%50.08
1.48%354.08
1.25%243.01
0.73%146.63
-5.33%393.19
-1.70%122.43
-0.61%153.65
-0.49%950.25
-0.35%211.25
-0.23%